Tourmaline Bio Inc (NASDAQ: TRML) on Friday, soared 3.87% from the previous trading day, before settling in for the closing price of $17.33. Within the past 52 weeks, TRML’s price has moved between $12.12 and $48.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 67.11%. With a float of $15.60 million, this company’s outstanding shares have now reached $25.64 million.
Let’s look at the performance matrix of the company that is accounted for 52 employees. In terms of profitability, gross margin is 49.12%, operating margin of -2628.43%, and the pretax margin is -2146.27%.
Tourmaline Bio Inc (TRML) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Tourmaline Bio Inc is 39.16%, while institutional ownership is 64.84%. The most recent insider transaction that took place on Aug 21 ’24, was worth 26,418. In this transaction CEO of this company bought 1,779 shares at a rate of $14.85, taking the stock ownership to the 7,000 shares. Before that another transaction happened on Aug 16 ’24, when Company’s CEO bought 5,221 for $13.79, making the entire transaction worth $71,998. This insider now owns 5,221 shares in total.
Tourmaline Bio Inc (TRML) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.87 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 67.11% per share during the next fiscal year.
Tourmaline Bio Inc (NASDAQ: TRML) Trading Performance Indicators
Tourmaline Bio Inc (TRML) is currently performing well based on its current performance indicators. A quick ratio of 40.33 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.82, a number that is poised to hit -0.87 in the next quarter and is forecasted to reach -3.52 in one year’s time.
Technical Analysis of Tourmaline Bio Inc (TRML)
Tourmaline Bio Inc (NASDAQ: TRML) saw its 5-day average volume 0.3 million, a positive change from its year-to-date volume of 0.22 million. As of the previous 9 days, the stock’s Stochastic %D was 9.64%. Additionally, its Average True Range was 1.40.
During the past 100 days, Tourmaline Bio Inc’s (TRML) raw stochastic average was set at 19.00%, which indicates a significant decrease from 19.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.36% in the past 14 days, which was lower than the 65.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.02, while its 200-day Moving Average is $19.32. Nevertheless, the first resistance level for the watch stands at $18.28 in the near term. At $18.57, the stock is likely to face the second major resistance level. The third major resistance level sits at $18.94. If the price goes on to break the first support level at $17.63, it is likely to go to the next support level at $17.26. Assuming the price breaks the second support level, the third support level stands at $16.97.
Tourmaline Bio Inc (NASDAQ: TRML) Key Stats
Market capitalization of the company is 461.57 million based on 25,643K outstanding shares. Right now, sales total 0 K and income totals -42,120 K. The company made 0 K in profit during its latest quarter, and -20,180 K in sales during its previous quarter.
